Immunotherapy has shown great promise to transform solid cancer treatment.

Monoclonal antibodies have become increasingly used therapeutic agents for the treatment of solid cancer.

The remaining 87 have suffered other complications, including four cases of solid cancer and two of leukaemia.

The concordance between both scoring systems was high in patients with infection but low in solid cancer.

The study included 40 solid cancer patients, 24 of whom showed distant organ metastases.

Plasma levels of GE-XDP and D-dimer, but not SF, were significantly high in patients with sepsis and solid cancer.

To explore this issue, DI was retrospectively analyzed in elderly patients treated with conventional CT regimens for advanced solid cancer.

Methods: This individual patient data meta-analysis evaluated (ultra)-LMWH in patients with solid cancer using data from seven randomized controlled trials.

We hypothesized that the tumor-specific TILs elicited and promoted by an OV would be a great source for ACT for solid cancer.

Here, we found that 2-HG depletion did not inhibit growth of several IDH1 mutant solid cancer types.

Anti-metastatic activity of an antitumor agent is exceedingly important because metastasis is the primary cause of death for most solid cancer patients.

G47Δ, a third-generation oncolytic herpes simplex virus type 1, is an attractive novel therapeutic agent for solid cancer.

This antiproliferative activity of the combined use of AZT and ddI at low, clinically applicable concentrations warrants clinical testing in human solid cancer.

While CAR T approach for the treatment of B cell malignancies has shown great success, response rates among patients with solid cancer are less favorable.

In conclusion, our preclinical results suggest that CD44v6.CAR T based adoptive therapy could be a promising strategy in solid cancer treatment.

The mRNA sequencing data from The Cancer Genome Atlas (TCGA) of 14 solid cancer types representing 6,685 tumor samples was analyzed.